Evogene Schedules First Quarter 2025 Financial Results Release
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a computational biology company focused on life-science product discovery and development, has announced it will release its Q1 2025 financial results on Wednesday, May 21, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time) on the same day. Interested participants can register for the conference call through the company's provided link. The conference recording will be made available on Evogene's website in the following days.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), un'azienda di biologia computazionale specializzata nella scoperta e sviluppo di prodotti per le scienze della vita, ha annunciato che pubblicher脿 i suoi risultati finanziari del primo trimestre 2025 il mercoled矛 21 maggio 2025. La societ脿 terr脿 una conference call per discutere i risultati alle 9:00 AM ET (16:00 ora di Israele) dello stesso giorno. Gli interessati possono registrarsi alla conference call tramite il link fornito dall'azienda. La registrazione della conferenza sar脿 disponibile sul sito web di Evogene nei giorni successivi.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), una empresa de biolog铆a computacional enfocada en el descubrimiento y desarrollo de productos para ciencias de la vida, ha anunciado que publicar谩 sus resultados financieros del primer trimestre de 2025 el mi茅rcoles 21 de mayo de 2025. La compa帽铆a realizar谩 una llamada conferencia para discutir los resultados a las 9:00 AM ET (16:00 hora de Israel) ese mismo d铆a. Los interesados pueden registrarse para la llamada a trav茅s del enlace proporcionado por la empresa. La grabaci贸n de la conferencia estar谩 disponible en el sitio web de Evogene en los d铆as siguientes.
Evogene Ltd. (雮橃姢雼�: EVGN, TASE: EVGN)電� 靸濍獏瓿柬暀 鞝滍拡 氚滉铂 氚� 臧滊皽鞐� 欷戩爯鞚� 霊� 瓿勳偘靸濍頃� 須岇偓搿滌劀, 2025雲� 1攵勱赴 鞛 瓴瓣臣毳� 2025雲� 5鞗� 21鞚� 靾橃殧鞚�鞐� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 臧欖潃 雮� 霃欕秬 響滌鞁� 鞓れ爠 9鞁� (鞚挫姢霛检棙 鞁滉皠 鞓ろ泟 4鞁�)鞐� 瓴瓣臣毳� 雲检潣頃橂姅 旎嵓霟办姢 旖滌潉 歆勴枆頃╇媹雼�. 甏�鞁� 鞛堧姅 彀戈皜鞛愲姅 須岇偓臧� 鞝滉车頃� 毵來伂毳� 韱淀暣 旎嵓霟办姢 旖滌棎 霌彪頃� 靾� 鞛堨姷雼堧嫟. 旎嵓霟办姢 雲轨潓鞚� 鞚错泟 氅办範 雮挫棎 Evogene 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Evogene Ltd. (Nasdaq : EVGN, TASE : EVGN), une soci茅t茅 de biologie computationnelle sp茅cialis茅e dans la d茅couverte et le d茅veloppement de produits en sciences de la vie, a annonc茅 qu'elle publiera ses r茅sultats financiers du premier trimestre 2025 le mercredi 21 mai 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique pour discuter des r茅sultats 脿 9h00 ET (16h00 heure d'Isra毛l) le m锚me jour. Les participants int茅ress茅s peuvent s'inscrire 脿 la conf茅rence via le lien fourni par la soci茅t茅. L'enregistrement de la conf茅rence sera disponible sur le site web d'Evogene dans les jours qui suivront.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), ein Unternehmen f眉r computergest眉tzte Biologie mit Fokus auf die Entdeckung und Entwicklung von Produkten im Bereich der Lebenswissenschaften, hat angek眉ndigt, seine Finanzergebnisse f眉r das erste Quartal 2025 am Mittwoch, den 21. Mai 2025 zu ver枚ffentlichen. Das Unternehmen wird am selben Tag um 9:00 Uhr ET (16:00 Uhr israelische Zeit) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Interessierte Teilnehmer k枚nnen sich 眉ber den bereitgestellten Link des Unternehmens f眉r die Telefonkonferenz anmelden. Die Aufzeichnung der Konferenz wird in den folgenden Tagen auf der Website von Evogene verf眉gbar sein.
- None.
- None.
Zoom conference call scheduled for May 21, 2025, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To join the conference, please register in advance:
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost听础滨, ChemPass AI听补苍诲听GeneRator AI. Each tech-engine聽is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
- Biomica Ltd.听()聽- developing and advancing novel microbiome-based therapeutics to treat human disorders powered by聽MicroBoost AI;
- Lavie Bio Ltd.听() - developing and commercially advancing, microbiome-based ag-biologicals powered by聽MicroBoost AI;
- AgPlenus Ltd. () - developing next-generation ag chemicals for effective and sustainable crop protection powered by聽ChemPass AI;
- Casterra Ag Ltd.听() - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by聽GeneRator AI.
For more information, please visit: .
Contact
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:
SOURCE Evogene
FAQ
When will Evogene (EVGN) release its Q1 2025 earnings?
What time is Evogene's Q1 2025 earnings call?
How can I join Evogene's Q1 2025 earnings call?
Will Evogene's Q1 2025 earnings call be available for replay?
